Paris, May 26th, 2026 – Opella announces the successful repricing of its two 1st Lien Term Loan B facilities, totaling approximately €4.97 billion equivalent.
The USD-denominated tranche, originally $3,781 million, has been decreased by $81 million, bringing the total to $3,700 million, and has been repriced with a 50-basis point reduction in margin. At the same time, the EUR-denominated tranche, originally €1,707 million, has been increased by €73 million, bringing the total to €1,780 million, and also benefited from a 50-basis point margin reduction. Citi and BNP Paribas acted as Global Coordinators for the USD and EUR tranches, respectively.
The repricing is leverage neutral and does not involve any other material changes to the terms and conditions of the facilities. The transaction is expected to generate approximately €24 million in annual interest savings.
This transaction reflects continued strong investor demand and confidence in Opella’s credit profile.
About Opella.
Opella is the self-care challenger with the purest and third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to bring health in people’s hands by making self-care as simple as it should be. For half a billion consumers worldwide – and counting. At the core of this mission is our 100 loved brands, our 11,000-strong global team, our 13 best-in-class manufacturing sites and 4 specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of the world’s most loved brands, including Allegra, Buscopan, Doliprane, Dulcolax, Enterogermina, Essentiale and Mucosolvan. B Corp certified globally, we are active players in the journey towards healthier people and planet.
Find out more about our mission at www.opella.com.
Contact.
Investor relations : investors@opella.com
In your pocket.
pdf version.
